







an Open Access Journal by MDPI

Frontiers in Flavivirus Vaccines

Guest Editors:

Dr. Sasha R. Azar

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA

Dr. Carlos A. Sariol

Unit of Comparative Medicine, School of Medicine, University of Puerto Rico, San Juan 00936, Puerto Rico

Deadline for manuscript submissions:

closed (30 September 2022)

Message from the Guest Editors

Dear Colleagues,

The past three decades have been characterized by an unprecedented emergence of various zoonotic viral agents. Of these, viruses within the Flavivirus genus of the family Flaviviridae are of particular concern to human health, as demonstrated by the global spread of West Nile virus. the explosive outbreaks of Zika in the Americas, and the enormous disease burden of the four dengue viruses. While vaccines for some Flaviviruses (YFV. JEV. TBEV) do exist, there are regional disparities in availability and usage. With the trend towards urbanization, deforestation, and global travel facilitating greater human-animal contact as well as the spread of invasive arthropod vectors beyond their original ranges, additional and novel Flavivirus vaccines, vaccine formulations, and strategies will be critical going forward. To that end, the present Special Issue will address advances in, as well as novel Flavivirus vaccines, vaccination strategies, vaccine formulations or technologies, and animal models describing correlates of protection.

Dr. Sasha R. Azar Dr. Carlos A. Sariol

Guest Editors













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us